8-K: SHF Holdings Secures $150M Equity Line with CREO

SHF Holdings, Inc. entered into a Common Stock Purchase Agreement with CREO Investments LLC, allowing the company to sell up to $150 million in Class A common stock for working capital and general corporate purposes.

Summary

• SHF Holdings, Inc. (the Company) entered into a Common Stock Purchase Agreement (CSPA) and a Registration Rights Agreement (RRA) with CREO Investments LLC (CREO) on September 17, 2025.
• The CSPA allows the Company to sell up to $150,000,000 of its Class A common stock to CREO, with the potential for mutual agreement to increase the total commitment up to $500,000,000.
• As consideration for CREO's commitment, the Company will issue $1.0 million in stated value of a to-be-designated series of preferred stock (Commitment Shares), which are fully earned as of the closing date.
• For every $100,000,000 increase in the Total Purchase Commitment, the Company will issue additional Commitment Shares with a value equal to 0.75% of such increased commitment.
• Shares will be purchased at a price equal to the lesser of 90% of (a) the lowest sale price of the common stock on the purchase date and (b) the volume-weighted average price (VWAP) during the purchase period.
• Initial sales are capped at 582,899 shares, representing 19.99% of the common stock outstanding immediately prior to the agreement, unless stockholder approval is obtained or sales are 'at market' under Nasdaq rules.
• CREO's beneficial ownership is limited to 4.99% of the outstanding common stock.
• The net proceeds from these sales are expected to be used for working capital and general corporate purposes.
• The Purchase Agreement will automatically terminate on the earliest of several conditions, including the 36-month anniversary of the closing date (September 17, 2028).

Sentiment

Score: 6

Explanation: The agreement provides a significant and flexible capital facility, which is positive for liquidity and growth. However, the potential for substantial shareholder dilution due to the discounted purchase price and the 'at-the-market' nature of sales introduces a notable negative aspect, balancing the overall sentiment.

Positives

• Secures a flexible equity financing facility of up to $150 million, with potential to increase to $500 million, providing a significant source of capital.
• The 'at-the-market' nature of the facility allows the company to control the timing and amount of share sales, potentially minimizing immediate market impact.
• Proceeds are designated for general corporate purposes and working capital, offering operational flexibility for strategic initiatives.
• The company receives $1.0 million in stated value of preferred stock as consideration for CREO's commitment, which is fully earned regardless of future purchases.

Negatives

• The equity line facility could lead to significant dilution for existing shareholders as new shares are issued at a discount (90% of VWAP or lowest sale price).
• The purchase price mechanism, being 90% of the lowest sale price or VWAP, means shares are sold below the prevailing market price, further contributing to dilution.
• The 19.99% Exchange Cap limits immediate capital access without shareholder approval, potentially delaying larger funding needs.
• A 'DTC Chill' event would result in an additional 10% discount on the purchase price and a $1,500 deduction per VWAP Purchase, increasing the cost of capital.
• The company is restricted from entering into other similar equity line or at-the-market offerings during the term of this agreement, limiting alternative financing options.

Risks

• Potential for significant dilution to existing stockholders due to the issuance of new common stock under the agreement.
• The net proceeds from the sales are uncertain and depend on the frequency of sales, number of shares sold, and prevailing market prices.
• Risk of delisting from Nasdaq if the common stock fails to meet listing requirements, which would trigger termination of the agreement.
• Risk of a 'DTC Chill' event, which would result in an additional 10% discount on the purchase price and a $1,500 deduction per VWAP Purchase, increasing capital costs.
• The company's ability to raise capital through other similar transactions is restricted during the term of this agreement.
• The company acknowledges that its obligation to issue commitment shares and shares under VWAP purchases is unconditional regardless of dilutive effect.

Future Outlook

The company expects to use any net proceeds from the sale of common shares to CREO for working capital and general corporate purposes, providing financial flexibility for future operations. Management believes this agreement offers beneficial flexibility for capital raising, subject to market conditions.

Management Comments

• Management of the Company believes that it is in the Company's best interests to have the flexibility to sell Common Shares pursuant to the Purchase Agreement, subject to market conditions.

Industry Context

This equity line of credit arrangement is a common financing mechanism for smaller public companies or those in growth phases, providing a flexible source of capital without the immediate dilution or upfront costs of a traditional underwritten offering. It allows the company to tap into capital as needed, aligning with market conditions, but also exposes it to potential dilution if share prices decline during drawdowns. The structure is typical for companies seeking to manage their capital structure dynamically.

Comparison to Industry Standards

• NA

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the issuance of new shares at a discount, but also benefits from enhanced company liquidity and funding for operations.
• Creditors: Improved financial stability and liquidity from the capital raise could reduce credit risk.
• Management: Gains flexibility in capital management and funding for strategic initiatives and working capital.

Next Steps

• File a Current Report on Form 8-K describing the material terms of the transaction.
• File a registration statement with the SEC covering the resale of common stock that may be issued to CREO under the Purchase Agreement by the Filing Deadline (30th Business Day after Closing Date).
• Maintain the continuous effectiveness of the registration statement during the Registration Period.
• The Company may, at its sole discretion, direct CREO to purchase shares of common stock under the agreement, subject to conditions.
• The Company will issue $1.0 million in stated value of preferred stock to CREO as commitment shares.

Key Dates

Recommendation

The equity line provides SHF Holdings with a flexible and substantial capital source, which is crucial for operational stability and growth initiatives. However, the inherent dilution risk from issuing shares at a discount (90% of VWAP or lowest sale price) and the potential for further dilution if the full $500 million commitment is utilized, warrants caution. While the capital infusion is positive, the mechanism of issuance could pressure the stock price. An investor would likely hold to monitor the company's execution of its strategy with the new capital and its ability to mitigate dilution effects, rather than immediately buying or selling based solely on this financing structure.

Keywords

Equity Line, Common Stock Purchase Agreement, Capital Raise, Dilution, SEC Filing, SHF Holdings, CREO Investments, Nasdaq, VWAP, Registration Rights